Lerato Mohapi to Anti-HIV Agents
This is a "connection" page, showing publications Lerato Mohapi has written about Anti-HIV Agents.
Connection Strength
1,321
-
The effect of a maturing antiretroviral program on early mortality for patients with advanced immune-suppression in Soweto, South Africa. PLoS One. 2013; 8(11):e81538.
Score: 0,236
-
STRETCHing delivery of HIV health services. Lancet. 2012 Sep 08; 380(9845):865-7.
Score: 0,216
-
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial. J Int AIDS Soc. 2022 06; 25(6):e25905.
Score: 0,107
-
HIV research in South Africa: Advancing life. S Afr Med J. 2019 Dec 05; 109(11b):36-40.
Score: 0,090
-
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study. Lancet HIV. 2019 09; 6(9):e588-e600.
Score: 0,087
-
Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study. Lancet HIV. 2017 01; 4(1):e13-e20.
Score: 0,072
-
Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial. Lancet. 2016 Mar 19; 387(10024):1198-209.
Score: 0,069
-
Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention. Clin Infect Dis. 2015 Oct 15; 61(8):1322-7.
Score: 0,066
-
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis. 2015 Jul; 15(7):793-802.
Score: 0,065
-
Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. Lancet. 2013 Jun 15; 381(9883):2091-9.
Score: 0,057
-
Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. PLoS Med. 2012; 9(6):e1001236.
Score: 0,053
-
Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med. 2012 Aug; 13(7):406-15.
Score: 0,052
-
Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS. 2010 Jul 17; 24(11):1679-87.
Score: 0,047
-
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis. 2010 Mar 15; 201(6):803-13.
Score: 0,046
-
Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine. Pharmacogenet Genomics. 2021 01; 31(1):17-27.
Score: 0,024
-
Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med. 2010 Oct 14; 363(16):1499-509.
Score: 0,012
-
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009 Mar 13; 23(5):631-6.
Score: 0,011
-
Costs of providing care for HIV-infected adults in an urban HIV clinic in Soweto, South Africa. J Acquir Immune Defic Syndr. 2009 Mar 01; 50(3):327-30.
Score: 0,011